Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22288890 | 0.93 | CYP1A2 (0.42) | GAATSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL2989825 | 0.86 | GAA (0.44) | GAATSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL31036085 | 0.86 | GAA (0.44) | GAATSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL14211018 | 0.83 | GAA (0.44) | GAATSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL12742256 | 0.75 | ALDH1A1 (0.53) | GAATSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL1507617 | 0.75 | ALDH1A1 (0.49) | GAATSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL15218940 | 0.75 | TSHR (0.53) | TSHRALDH1A1CYP3A4MAPTHSD17B10 | |
| SCHEMBL14790415 | 0.75 | KDM4E (0.33) | TSHRALDH1A1CYP3A4MAPTCYP1A2 | |
| SCHEMBL14739198 | 0.75 | VCAM1 (0.47) | GAATSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL19204032 | 0.75 | GAA (0.38) | GAATSHRALDH1A1CYP3A4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| EP-3807274-B1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
| EP-3807274-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | Lead Discovery Center GmbH (DE) | 2021-04-21 | — | — | EP | disclosed |
| CN-112585138-A | 4-substituted pyrrolo [2,3-b ] pyridines as ErbB modulators useful in the treatment of cancer | 利德探索中心有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020039060-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | ERBB2, ERBB4, ERBB3 | GAA 3641/4885TSHR 783/4885ALDH1A1 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.